Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: Standard-dose therapy followed by reduced-dose therapy

American Journal of Obstetrics and Gynecology

Volumn 175, Issue 5, 1996, Pages 1208-1216

  Broekmans, F J ^a   Hompes, P G A ^a   Heitbrink, M A ^a   Netelenbos, C C ^a   Roos, J C ^a   Falke, T M ^a   Schoemaker, J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

bone mineral density; dose study; gonadotropin releasing hormone agonist; leiomyomas; Triptorelin

Indexed keywords

GONADORELIN AGONIST; TRIPTORELIN;

ADULT; AMENORRHEA; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; DOSE RESPONSE; FEMALE; HORMONAL REGULATION; HOT FLUSH; HUMAN; HYPOPHYSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VOLUME; UTERUS MYOMA;

EID: 0029966756     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(96)70030-3     Document Type: Article

References (24)

1. 6-luteinizing hormone-releasing hormone Fertil Steril 48 1987 383 389
2. R Maheux A Lemay P Blanchet J Friede X. Pratt Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone - releasing hormone agonist implant: a pilot study Hum Reprod 6 1991 500 505
3. AJ Friedman M Daly M Juneau-Norcross R Gleason MS Rein M. Leboff Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin “add back” for 2 years Hum Reprod 9 1994 1618 1625 3a. Broekmans FJ, Heitbrink MA, Hompes PGA, Schouten E, Falke ThM, Schoemaker J. Quantitative MR imaging of uterine leiomyomas during triptorelin treatment: reproducibility of volume assessment and predictability of treatment response. Magn Reson Imaging (in press).
4. FJ Broekmans RE Bernardus A Broeders G Berkhout J. Schoemaker Pituitary responsiveness after administration of a GnRH agonist depot formulation: Decapeptyl CR Clin Endocrinol (Oxf) 38 1993 579 587
5. JL. Fleisch The parallel groups design The design and analysis of clinical experiments 1986 John Wiley New York 46 72
6. AJ Friedman SM Lobel MS Rein RL. Barbieri Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis Am J Obstet Gynecol 163 1990 1114 1119
7. Y Watanebe M Nozaki G Nakamura M Sano H Matsuguchi H. Nakano Efficacy of low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women Fertil Steril 58 1992 66 71
8. J Balasch F Gomez R Casamitjana F Carmona F Rivera JA. Vanrell Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot Hum Reprod 7 1992 1230 1234
9. J Happ H Schultheiss GH Jacobi Pharmacodynamics, pharmacokinetics and bioavailability of the prolonged LH-RH agonist Decapeptyl-SR JGM Klijn Hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents. 1987 Raven Press New York 249 253
10. JA Gudmundsson SJ Nillius C. Bergquist Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH Contraception 30 1984 107 112
11. F Geisthoevel D Jenne P Wieacker M. Breckwoldt Cyclic administration of an LHRH analogue and to progesterone in risk patients to oral contraceptives Contraception 36 1987 459 469
12. R Maheux A Lemay L. Turcot Lemay Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma Am J Obstet Gynecol 158 1988 361 364
13. JE Hall TD Brodie TM Badger Evidence of differential control of FSH and LH secretion by gonadotropin-releasing hormone (GnRH) from the use of a GnRH antagonist J Clin Endocrinol Metab 67 1988 524 531
14. FJ Broekmans PG Hompes CB Lambalk E Schoute A Broeders J. Schoemaker Short term pituitary desensitisation: effects of different doses of the GnRH agonist triptorelin Hum Reprod 11 1996 55 60
15. SE Monroe Z Blumenfeld JL Andreyko E Schriock MR Henzl RB. Jaffe Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin) J Clin Endocrinol Metab 63 1986 1334 1341
16. T Uemura H Minaguchi K Okuda O. Sugimoto GnRH agonist Zoladex in the treatment of endometriosis B Lunenfeld Advances in the study of GnRH analogues. Proceedings of the 2nd international symposium on GnRH analogues in cancer and human reproduction. 1992 Parthenon Carnforth, Lancaster (UK) 159 171
17. R Maheux C Guilloteau A Lemay A Bastide AT. Fazekas Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study Am J Obstet Gynecol 152 1985 1034 1038
18. R Maheux A Lemay P. Merat Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas Fertil Steril 47 1987 229 233
19. T Uemura H Minaguchi M Mizuno O Tanizawa O. Sugimoto The effects of GnRH agonist (buserelin) on uterine leiomyoma: clinical study on finding the optimal dose I Brosens HS Jacobs B Runnebaum LHRH analogues in gynaecology. 1990 Parthenon Carnforth 101 110
20. T Jaakkola YQ Ding P Kellokumpu Lehtinen The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay J Clin Endocrinol Metab 70 1990 1496 1505
21. SG Hillier PF Whitelaw CD. Smyth Follicular oestrogen synthesis: the “two-cell, two-gonadotrophin” model revisited Mol Cell Endocrinol 100 1994 51 54
22. RS. Rittmaster Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide J Clin Endocrinol Metab 67 1988 651 655
23. EY. Adashi Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal “add-back” paradigms Hum Reprod 9 1994 1380 1397
24. T Uemura N Suzuki J Mohri N Katagiri H Osada H. Minaguchi Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis Fertil Steril 62 1994 246 250